Jazz Pharmaceuticals Announces First Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Jazz Pharmaceuticals (JAZZ) PT Raised to $208 at BMO Capital
May 8, 2019 7:48 AM EDTBMO Capital analyst Gary Nachman raised the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $208.00 (from $206.00) while maintaining a Outperform rating.
Nachman commented, "JAZZ delivered strong, high-quality 1Q results with impressive beats on both top and bottom lines while maintaining robust spending... More
Jazz Pharmaceuticals (JAZZ) Tops Q1 EPS by 51c
May 7, 2019 4:17 PM EDTJazz Pharmaceuticals (NASDAQ: JAZZ) reported Q1 EPS of $3.67, $0.51 better than the analyst estimate of $3.16. Revenue for the quarter came in at $508.2 million versus the consensus estimate of $465.95 million.
GUIDANCE:
Jazz Pharmaceuticals sees FY2019 EPS of $14.30-$15.00, versus the consensus of $14.60.... More
